{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=45",
    "query": {
      "intervention": "Safety Control",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 14130,
    "total_pages": 1413,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=46&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=44&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T02:12:37.522Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01146925",
      "title": "Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Contrast-Induced Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "CRMD-001-Deferiprone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CorMedix Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2010-06",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2011-06-27",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 8,
      "location_summary": "Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Petoskey",
          "state": "Michigan"
        },
        {
          "city": "Southfield",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01146925"
    },
    {
      "nct_id": "NCT00365976",
      "title": "Study of the Insomnia in Patients With Low Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Insomnia"
      ],
      "interventions": [
        {
          "name": "Eszopiclone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "21 Years to 64 Years"
      },
      "enrollment_count": 58,
      "start_date": "2006-08",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2015-07-24",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00365976"
    },
    {
      "nct_id": "NCT02960217",
      "title": "Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2017-04-19",
      "completion_date": "2019-10-09",
      "has_results": true,
      "last_update_posted_date": "2020-06-16",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Miami, Florida • Norcross, Georgia + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Norcross",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960217"
    },
    {
      "nct_id": "NCT05445518",
      "title": "Jump Start Plus COVID-19 Support",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mental Health Wellness 1"
      ],
      "interventions": [
        {
          "name": "Jump Start Plus COVID Support",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Healthy Caregivers-Healthy Children (HC2)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 1505,
      "start_date": "2022-08-01",
      "completion_date": "2026-05-19",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05445518"
    },
    {
      "nct_id": "NCT00855920",
      "title": "Study Utilizing Rilonacept in Gout Exacerbations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Gout Flare"
      ],
      "interventions": [
        {
          "name": "Rilonacept",
          "type": "DRUG"
        },
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Indomethacin)",
          "type": "OTHER"
        },
        {
          "name": "Placebo (for Rilonacept)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 225,
      "start_date": "2009-03",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sierra Vista",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00855920"
    },
    {
      "nct_id": "NCT03548220",
      "title": "A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pyruvate Kinase Deficiency",
        "Anemia, Hemolytic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AG-348",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2018-08-09",
      "completion_date": "2020-10-09",
      "has_results": true,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 12,
      "location_summary": "Little Rock, Arkansas • Atlanta, Georgia • Indianapolis, Indiana + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03548220"
    },
    {
      "nct_id": "NCT05798923",
      "title": "LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension Due to Lung Diseases and Hypoxia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LAM-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IRulya Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 85,
      "start_date": "2023-08-30",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 4,
      "location_summary": "Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05798923"
    },
    {
      "nct_id": "NCT00468559",
      "title": "Phase 3/Safety & Efficacy of Esomeprazole in Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Open Label Run In Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Double Blind Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Double Blind Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "11 Months",
        "sex": "ALL",
        "summary": "1 Month to 11 Months"
      },
      "enrollment_count": 98,
      "start_date": "2007-04",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2014-06-02",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Marrero",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00468559"
    },
    {
      "nct_id": "NCT01587079",
      "title": "Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT003",
          "type": "DRUG"
        },
        {
          "name": "PT001",
          "type": "DRUG"
        },
        {
          "name": "PT005",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium inhalation powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 159,
      "start_date": "2012-04",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2016-06-30",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 19,
      "location_summary": "Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01587079"
    },
    {
      "nct_id": "NCT02481674",
      "title": "A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "VX15/2503",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vaccinex Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 301,
      "start_date": "2015-07",
      "completion_date": "2020-08",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-11-05T02:12:37.522Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481674"
    }
  ]
}